Pediatr. praxi. 2022;23(1):13-17 | DOI: 10.36290/ped.2022.002

Inflammatory bowel disease in children - part 2: treatment and complications

MUDr. Nabil El-Lababidi
Centrum dětské gastroenterologie, hepatologie a výživy, Klinika pediatrie a dědičných poruch metabolismu (KPDPM) VFN a 1. LF UK, Praha

Inflammatory bowel disease (IBD) is a group of inflammatory illnesses affecting the gastrointestinal tract. While the first part of this paper focused on IBD from aetiology to establishing the diagnosis, this part focuses on treatment and complications of IBD. Treatment should be guided by ESPGHAN (European Society for Paediatric Gastroenterology, Hepatology and Nutrition) guidelines. Treatment goals consist of reaching and maintaining remission. This can be achieved in case of Crohn's disease (CD) with nutritional intervention, in addition to pharmacotherapy and in certain indicated cases with surgical intervention. Stricture formations and fistulas are among possible CD complications. Ulcerative colitis is associated with risk of development of acute severe colitis (ASC) or toxic megacolon

Keywords: Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, remission, relapse, treatment - dietary, pharmacological, surgical, complications - strictures, fistulas, acute severe colitis, toxic megacolon.

Published: February 23, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
El-Lababidi N. Inflammatory bowel disease in children - part 2: treatment and complications. Pediatr. praxi. 2022;23(1):13-17. doi: 10.36290/ped.2022.002.
Download citation

References

  1. McDowell C, Farooq U, Haseeb M. Inflammatory Bowel Disease (Updated 1.7.2021). In. StarPearls (Internet). Treasure Island (FL): StarPearls Publishing 2021.
  2. Ouahed J, Spencer E, Kotlarz D, et al. Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficincies. Inflamm Bowel Dis. 2020;26(6):820-842. Go to original source... Go to PubMed...
  3. Thurgate LE, Lemberg DA, Da AS, et al. An Overview of Inflammatory Bowel Disease Unclassified in Children. Inflamm Intest Dis. 2019;4(3):97-103. Go to original source... Go to PubMed...
  4. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014;8(10):1179-207. Go to original source... Go to PubMed...
  5. Benchimol EL, Fortinsky KJ Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systemic review of international trends. Inflamm Bowel Dis. 2011;17(1):423-439. Go to original source... Go to PubMed...
  6. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5(12):1424-1429. Go to original source... Go to PubMed...
  7. Schwarz J, Sýkora J, Cvalínová D, et al. Inflammatory bowel disease incidence in Czech children: A regional prospective study, 2000-2015. World J Gastroenterol. 2017;23(22):4090-4101. Go to original source... Go to PubMed...
  8. Ghione S, Sarter H, Fumery M, et al. EPIMAD Group. Dramatic increase in incidence of ulcerative colitis and Crohn's disease [1988-2011]: a population-based study of French adolescents. Am J Gastroenterol. 2018;113:265-272. Go to original source... Go to PubMed...
  9. Turner D, Ruemmele FM, Orlansko-Meyer E, et al. Management of Pediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline from European Crohn's and Colitis Organization European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):257-291. Go to original source... Go to PubMed...
  10. Van Limbergen J, Russel RK, Drummond HE, et al. Definition of phenotypic characteristic of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114-1122. Go to original source... Go to PubMed...
  11. Benchimol EI. Bernstein CN, Bitton A, et al. Trends In Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases. Am J Gastroenterol. 2017;112(7):1120-1134. Go to original source... Go to PubMed...
  12. Sartor R. Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Rev Gastroenterol Hepatol. 2006;3:390-407. Go to original source... Go to PubMed...
  13. Feuerstein JD, Cheifetz AS. Crohn Disease: Epidemiology, Diagnosis and Management. Mayo Clin Proc. 2017;92(7):1088-1103. Go to original source... Go to PubMed...
  14. Ng SC, Bernnstein CN, Vatn MH, et al. Epidemiology and Natural History Task Force of the International Organization of Inflammatory Bowel Disease (IOIBD). Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013;62:630-649. Go to original source... Go to PubMed...
  15. Philpott DJ, Viala J. Towards and understanding of the role of NOD2/CARD15 in the pathogenesis of Crohn's disease. Best Pract Res Clin Gastroenterol. 2004;18:555-568. Go to original source... Go to PubMed...
  16. Wang MH, Achkar JP. Gene-environment interactions in inflammatory bowel disease pathogenesis. Curr Opin Gastro­enterol. 2015;31:277-282. Go to original source... Go to PubMed...
  17. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and future ahead. Gastroenterology. 2014;146:1489-1499. Go to original source... Go to PubMed...
  18. Kronman MP, Zaoutis TE, Haynes K, et al. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics. 2012;130:e794-e803. Go to original source... Go to PubMed...
  19. Kaplan GG, Jackson T, Sands BE, et al. The risk of developing Crohn's disease after an appendectomy: a meta-analysis. Am J Gastroenerol. 2008;103:2925-2931. Go to original source... Go to PubMed...
  20. Agus A, Denizot J, Thévenot J, et al. Western diet induces a shift in microbiota composition enhancing susceptibility to Adherent-Invasive E. coli infection and intestinal inflammation. Sci Rep. 2016;6:19032. doi: 10.1038/srep19032. Go to original source... Go to PubMed...
  21. Martinez-Medina M, Denizot J, Dreux N, et al Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut. 2014;63(1):116-124. doi: 10.1136/gutjnl-2012-304119. Go to original source... Go to PubMed...
  22. Ananthakrishnan AN, Khalil IH, Konijeti GG, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn´s disease and ulcerative colitis. Gastroenterology. 2013;145(5):970-977. doi: 10.1053/j.gastro.2013.07.050. Go to original source... Go to PubMed...
  23. Desai MS, Seekatz AM, Koropatkin NM, et al. A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility. Cell. 2016;167(5):1339-1353. doi: 10.1016/j.cell.2016.10.043. Go to original source... Go to PubMed...
  24. Wagner SJ, Schmidt A, Effenberger MJ, et al. Semisynthetic diet ameliorates Crohn's disease-like ileitis in TNFΔARE/WT mice through antigen-independent mechanisms of gluten. Inflamm Bowel Dis. 2013;19(6):1285-1294. Go to original source... Go to PubMed...
  25. Chassaing B, Koren O, Goodrich JK, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015;519(7541):92-96. doi: 10.1038/nature14232. Go to original source... Go to PubMed...
  26. Chassaing B, Van de Wiele T, De Bodt J, et al. Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation. Gut. 2017;66(8):1414-1427. doi: 10.1136/gutjnl-2016-313099. Go to original source... Go to PubMed...
  27. Nickerson KP, Chanin R, McDonald C. Dysregulation of intestinal anti-microbial defense by the dietary additive, malto­dextrin. Gut Microbes. 2015;6(1):78-83. doi: 10.1371/journal.pone.0101789. Go to original source... Go to PubMed...
  28. Nickerson KP, Homer CR, Kessler SP, et al. The dietary polysaccharide maltodextrin promotes Salmonella survival and mucosal colonization in mice. PLoS One. 2014;9(7):e101789. doi: 10.1371/journal.pone.0101789. Go to original source... Go to PubMed...
  29. Fahoum L, Moscovici A, David S, et al. Digestive fate of dietary carrageenan: Evidence of interference with digestive proteolysis and disruption of gut epithelial function. Mol Nutr Food Res 2017;161(3). doi: 10.1002/mnfr.201600545. Go to original source... Go to PubMed...
  30. Diefenbach KA, Breuer CK, et al. Pediatric inflammatory bowel disease. World J Gastroenterol. 2006;12(20): 3204-3212. Go to original source... Go to PubMed...
  31. Däbritz J, Gerner P, Enninger A, et al. Inflammatory Bowel Disease in Childhood and Adolescence. Dtsch Arztebl Int. 2017;114(19):331-338. Go to original source... Go to PubMed...
  32. Jang H-J, Kang B, Choe B-H. The difference in extraintestinal manifestations of inflammatory bowel disease for children and adults. Transl Pediatr. 2019;8(1):4-15. Go to original source... Go to PubMed...
  33. Stawarski A, Iwańczak B, Krzesiek E, et al. Intstinal complications and extraintestinal manifestations in children with inflammatory bowel disease. Pol Merkur Lekarski. 2006;20(115):22-25. Go to PubMed...
  34. Dotson JL, Hyams JS, Markowitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr. 2010;51(2):140-145. Go to original source... Go to PubMed...
  35. Oliviera SB, Monteiro IM. Diagnosis and management of inflammatory bowel disease in children. BMJ 2017;357:2083. Go to original source... Go to PubMed...
  36. Levine A, Koletzko S, Turner D, et al. ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents. J Pediatr Gastroenterol Nutr. 2014;58(6):795-806. Go to original source... Go to PubMed...
  37. Eriksson C, Hendriksson I, Brus O, et al. Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population-based cohort study. Aliment Pharmacol Ther. 2018;48(6):638-645. Go to original source... Go to PubMed...
  38. Sabery N, Bass D. Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia. Pediatrics. 2007;119(1):e193-199. Go to original source... Go to PubMed...
  39. Cabrera-Abreu JC, Davies P, Matek Z, et al. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child. 2004;89(1):69-71.
  40. Fagerberg UL, Lööf L, Lindholm J, et al. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45(4):414-420. Go to original source... Go to PubMed...
  41. Hyams JS, Markowitz JF. Can we alter the natural history of Crohn disease in children? J Pediatr Gastroenterol Nutr. 2005;40(3):262-272. Go to original source... Go to PubMed...
  42. Mack DR, Langton C, Markowitz J, et al. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics. 2007;119(6):1113-1119. Go to original source... Go to PubMed...
  43. de Bie CI, Buderus S, Sandhu BK, et al. Diagnostic workup of paediatric patients with inflammatory bowel disease in Europe: results of a 5-year audit of the EUROKIDS registry. J Pediatr Gastroenterol Nutr. 2012;54(3):374-380. Go to original source... Go to PubMed...
  44. Kovacs M, Muller KE, Arato A, et al. Diagnostic yield of upper endoscopy in paediatric patients with Crohn´s disease and ulcerative colitis. Subanalysis of the HUPIR registry. J Crohns Colitis. 2021;6(1):86-94. Go to original source... Go to PubMed...
  45. Paerregaard A. What does the IBD patient hide in the upper gastrointestinal tract? Inflamm Bowel Dis. 2009;15:1101-1104. Go to original source... Go to PubMed...
  46. Goodsall TM, Nguyen TM, Parker CE, et al. Systematic Review: Gastrointestinal Ultrasound Scoring Indices for Inflammatory Bowel Disease. J Crohns Colitis. 2021;15(1):125-142. Go to original source... Go to PubMed...
  47. Liao Z, Gaor R, Xu C, et al. Indications and detection, completion, and retention rates of small-bowel capsule endoscopy: a systemic review. Gastrointest Endosc. 2010;71:280-286. Go to original source... Go to PubMed...
  48. Cheifetz AS, Kornbluth AA, Legnani P, et al. The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease. Am J Gastroenterol. 2006;101:2218-2222. Go to original source... Go to PubMed...
  49. Fritscher-Ravens A, Scherbakov P, Bufler P, et al. The feasibility of wireless capsule endoscopy in detecting small intestinal pathology in children under the age of 8 years: a multicentre European study. Gut. 2009;58:1467-1472. Go to original source... Go to PubMed...
  50. van Rheenen PF, Aloi M, Assa A, et al. The Medical Mana­gement of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis. 2021;171-194. Go to original source... Go to PubMed...
  51. Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. Lancet. 2017;389:1710-1718. Go to original source... Go to PubMed...
  52. Khan KJ, Ullman TA, Ford C, et al. Antibiotic therapy in inflammatory bowel disease: a systemic review and meta-analysis. Am J Gastronetreol. 2011;106:661-673. Go to original source... Go to PubMed...
  53. Scherkenbach LA, Stumpf JL. Methotrexate for the management of Crohn's disease in children. Ann Pharmacother. 2016;50:60-69. Go to original source... Go to PubMed...
  54. Levine A, Wine E, Assa A, et al. Crohn´s Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. Gastroenterology. 2019;157(2):440-450.e8. Go to original source... Go to PubMed...
  55. Sigall-Boneh R, Pfeffer-Gik T, Segal I, et al. Partial Enteral Nutrition with a Crohn´s Disease Exclusion Diet is Effective for Induction of Remission in Children and Young Adults with Crohn´s Disease. Inflamm Bowel Dis. 2014;20:1353-1360. Go to original source... Go to PubMed...
  56. Sigall-Boneh R, Sarbagili Shabat CS, Yanai H, et al. Dietary Therapy With the Crohn´s Disease Exclusion Diet is a Successful Strategy for Induction of Remission in Children and Adults Failing Biological Therapy. J Crohns Colitis. 2017;11(10):1205-1212. Go to original source... Go to PubMed...
  57. Svolos V, Hansen R, Nichols B, et al. Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition. Gastroenterology. 2019;156(5):1354-1367.e6. Go to original source... Go to PubMed...
  58. Regueiro M, Feagan BG, Zou B, et al. PREVENT Study Group. Infliximab reduces endoscopis, but not clinical recurrence of Crohn's disease after ileocolonic resection. Gastroenterology. 2016;150:1568-1578. Go to original source... Go to PubMed...
  59. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Mana­gement of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):292-310.Další literatura u autora a na www.pediatriepropraxi.cz Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.